MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s12882-024-03466-5

Медицинская библиотека · BMC nephrology · 2024

Screening, identifying, and treating chronic kidney disease: why, who, when, how, and what?

Farrell Douglas R, Vassalotti Joseph A

СтатьяОбзорПеревод в очереди

Аннотация

1 in 7 American adults have chronic kidney disease (CKD); a disease that increases risk for CKD progression, cardiovascular events, and mortality. Currently, the US Preventative Services Task Force does not have a screening recommendation, though evidence suggests that screening can prevent progression and is cost-effective. Populations at risk for CKD, such as those with hypertension, diabetes, and age greater than 50 years should be targeted for screening. CKD is diagnosed and risk stratified with estimated glomerular filtration rate utilizing serum creatinine and measuring urine albumin-to-creatinine ratio. Once identified, CKD is staged according to C-G-A classification, and managed with lifestyle modification, interdisciplinary care and the recently expanding repertoire of pharmacotherapy which includes angiotensin converting enzyme inhibitors or angiotensin-II receptor blockers, sodium-glucose-cotransporter-2 inhibitors, and mineralocorticorticoid receptor antagonists. In this paper, we present the why, who, when, how, and what of CKD screening.

Для цитирования: Farrell Douglas R, Vassalotti Joseph A. Screening, identifying, and treating chronic kidney disease: why, who, when, how, and what?. BMC nephrology. 2024. DOI: 10.1186/s12882-024-03466-5.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.